Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme

NCT01648348 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

116

Enrollment

NIH

Sponsor class

Conditions

Adult Anaplastic Astrocytoma
Adult Anaplastic Oligodendroglioma
Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma
Adult Mixed Glioma
Recurrent Adult Brain Neoplasm

Interventions

BIOLOGICAL: Anti-Endoglin Chimeric Monoclonal Antibody TRC105
BIOLOGICAL: Bevacizumab
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
OTHER: Quality-of-Life Assessment

Sponsor

National Cancer Institute (NCI)